Key Insights

Highlights

Success Rate

96% trial completion (above average)

Published Results

11 trials with published results (31%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

2.8%

1 terminated out of 36 trials

Success Rate

95.7%

+9.1% vs benchmark

Late-Stage Pipeline

22%

8 trials in Phase 3/4

Results Transparency

50%

11 of 22 completed with results

Key Signals

11 with results96% success

Data Visualizations

Phase Distribution

30Total
Not Applicable (11)
Early P 1 (2)
P 1 (4)
P 2 (5)
P 3 (5)
P 4 (3)

Trial Status

Completed22
Recruiting5
Unknown4
Not Yet Recruiting2
Withdrawn2
Terminated1

Trial Success Rate

95.7%

Benchmark: 86.5%

Based on 22 completed trials

Clinical Trials (36)

Showing 20 of 20 trials
NCT05753813Early Phase 1Recruiting

Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome

NCT05507333Not ApplicableCompletedPrimary

Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis

NCT06954493Phase 1CompletedPrimary

Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp

NCT03761628Not ApplicableCompletedPrimary

Clinical Performance of a Vaginal Pessary (pHyph) in Vulvovaginal Candidiasis

NCT07044947Not Yet RecruitingPrimary

Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis(VVC)

NCT06480604Not ApplicableRecruitingPrimary

Effect of a Multi-strain Probiotic on Recurrent Vulvovaginal Candidiasis

NCT05908682RecruitingPrimary

Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes

NCT05399641Phase 3CompletedPrimary

Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

NCT06450990Phase 1Not Yet Recruiting

Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection

NCT06397248RecruitingPrimary

DeVEnIR: Defining Vulvovaginal Candidiasis - Elements of Infection and Remedy

NCT05079711RecruitingPrimary

Comparative Performance of a Vaginal Yeast Test

NCT01039584Not ApplicableCompletedPrimary

A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations

NCT05895162Not ApplicableUnknownPrimary

Zinc-containing Vaginal Gel and Oral Fluconazole for Vulvovaginal Candidiasis.

NCT05552378Not ApplicableCompletedPrimary

Multi-Gyn FloraFem Study for Treatment of Vulvo Vaginal Candidiasis Symptoms

NCT05327192CompletedPrimary

VVC Sampling Study for Analysis Validation

NCT05031481Phase 2WithdrawnPrimary

Efficacy and Safety of Different Doses of Venus Association in Patients With Vulvovaginal Candidiasis.

NCT00803738Not ApplicableCompletedPrimary

Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis

NCT05012852Not ApplicableUnknown

Evaluation of VagiVitalAC for Treatment of Candida Vulvovaginitis

NCT01806623Phase 3CompletedPrimary

The Study Of Fluconazole For Vulvovaginal Candidiasis

NCT02180100Phase 4CompletedPrimary

Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis

Scroll to load more

Research Network

Activity Timeline